Co-Authors
This is a "connection" page, showing publications co-authored by COLIN P DINNEY and SHARADA MOKKAPATI.
Connection Strength
3.155
-
Lentiviral interferon: A novel method for gene therapy in bladder cancer. Mol Ther Oncolytics. 2022 Sep 15; 26:141-157.
Score: 0.837
-
TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Mol Cancer Res. 2020 06; 18(6):811-821.
Score: 0.715
-
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon a gene therapy in a murine bladder cancer model. Front Immunol. 2024; 15:1387229.
Score: 0.247
-
Minimal Residual Disease Detection with Urine-derived DNA Is Prognostic for Recurrence-free Survival in Bacillus Calmette-Gu?rin-unresponsive Non-muscle-invasive Bladder Cancer Treated with Nadofaragene Firadenovec. Eur Urol Oncol. 2024 Oct 14.
Score: 0.246
-
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward. Bladder Cancer. 2024; 10(2):105-112.
Score: 0.241
-
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval. Front Immunol. 2023; 14:1260498.
Score: 0.228
-
The current status of gene therapy in bladder cancer. Expert Rev Anticancer Ther. 2023 05; 23(5):531-543.
Score: 0.222
-
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. Oncoimmunology. 2019; 8(5):e1577125.
Score: 0.166
-
The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol. 2019 Oct; 37(10):2041-2049.
Score: 0.163
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.051
-
Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 02; 121(2):244-251.
Score: 0.038